Cutaneous reactions to drugs

Adverse reactions to medications are common and important cause of iatrogenic illness. Severe cutaneous adverse drug reactions include toxic epidermal necrolysis, Stevens–Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis, which together constitute 2% of all adverse drug reactions and may be life-threatening. Less severe drug-induced skin reactions such as exanthems, urticaria, lichenoid drug rashes, and fixed drug eruptions are more common, sometimes termed benign cutaneous adverse reactions, and generally resolve without sequelae. Drugs may also cause adverse events due to alteration of the normal function of the skin or its appendages. This may take the form of photosensitivity, abnormal pigmentation, or disrupted growth of hair or nails.

[1]  Zackery Bullard,et al.  Warfarin-Induced Skin Necrosis , 2014, Hospital pharmacy.

[2]  D. Creamer,et al.  Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking , 2011, Clinical and experimental dermatology.

[3]  G. Piérard,et al.  New Insights in Toxic Epidermal Necrolysis (Lyell’s Syndrome) , 2010, Drug safety.

[4]  B. K. Park,et al.  Food , drug , insect sting allergy , and anaphylaxis Stimulation of human T cells with sulfonamides and sulfonamide metabolites , 2022 .

[5]  P. Brennan,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to mAbs : 105 desensitizations in 23 patients , from evaluation to treatment , 2011 .

[6]  A. Marzano,et al.  Drug-induced lupus: an update on its dermatologic aspects , 2009, Lupus.

[7]  S. Calvieri,et al.  Amoxicillin–clavulanic acid‐induced linear immunoglobulin A bullous dermatosis: case report and review of the literature , 2009, International journal of dermatology.

[8]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[9]  A. Gottlieb,et al.  Dermatological complications and safety of anti-TNF treatments , 2009, Gut.

[10]  A. Gottlieb,et al.  Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. , 2009, Journal of the American Academy of Dermatology.

[11]  E. Guevara-Gutiérrez,et al.  Acute generalized exanthematous pustulosis: report of 12 cases and literature review , 2009, International journal of dermatology.

[12]  M. Mockenhaupt Severe drug‐induced skin reactions: clinical pattern, diagnostics and therapy , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[13]  T. Kuo,et al.  Clinicopathlogical features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  H. Justiniano,et al.  Pattern Analysis of Drug-Induced Skin Diseases , 2008, The American Journal of dermatopathology.

[15]  E. Phillips,et al.  A review of drug patch testing and implications for HIV clinicians , 2008, AIDS.

[16]  A. Segal,et al.  Cutaneous Reactions to Drugs in Children , 2007, Pediatrics.

[17]  H. Uchi,et al.  Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity? , 2007, Dermatology.

[18]  J. Albrecht,et al.  Drug-associated lymphoma and pseudolymphoma: recognition and management. , 2007, Dermatologic clinics.

[19]  E. Cowen Epidermal growth factor receptor inhibitors: a new era of drug reactions in a new era of cancer therapy. , 2007, Journal of the American Academy of Dermatology.

[20]  S. Helfgott,et al.  Serum sickness following treatment with rituximab. , 2007, The Journal of rheumatology.

[21]  J. Tolland,et al.  Voriconazole‐induced pseudoporphyria , 2007, Photodermatology, photoimmunology & photomedicine.

[22]  A. Bircher,et al.  Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options , 2006, Allergy.

[23]  M. Tohyama,et al.  Reactivation of human herpesvirus (HHV) family members other than HHV‐6 in drug‐induced hypersensitivity syndrome , 2006, The British journal of dermatology.

[24]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[25]  A. Barbaud Drug patch testing in systemic cutaneous drug allergy. , 2005, Toxicology.

[26]  N. Scheinfeld Impact of phenytoin therapy on the skin and skin disease , 2004, Expert opinion on drug safety.

[27]  M. Britschgi,et al.  Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells , 2002, Current opinion in allergy and clinical immunology.

[28]  A. Gaspari,et al.  Nonsteroidal Antiinflammatory Drug-Induced Pseudoporphyria: A Case Series , 2002, Journal of cutaneous medicine and surgery.

[29]  M. Gonçalo,et al.  Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions , 2001, Contact dermatitis.

[30]  M. Bigby Rates of cutaneous reactions to drugs. , 2001, Archives of dermatology.

[31]  N. Shear,et al.  A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. , 2000, Clinical biochemistry.

[32]  J. Uetrecht,et al.  Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? , 2000, Current drug metabolism.

[33]  C. González‐Herrada,et al.  Treatment of toxic epidermal necrolysis with cyclosporin A. , 2000, The Journal of trauma.

[34]  R. Patterson,et al.  Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. , 2000, Allergy and asthma proceedings.

[35]  C. Lovell,et al.  Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline‐induced lupus‐like syndrome , 2000, The British journal of dermatology.

[36]  N. Shear,et al.  What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions? , 2000, The British journal of dermatology.

[37]  K. Pramatarov Drug-induced lupus erythematosus. , 1998, Clinics in dermatology.

[38]  G. Kearns,et al.  Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. , 1994, The Journal of pediatrics.

[39]  W. Bergfeld,et al.  Amiodarone-induced linear IgA disease. , 1994, Journal of the American Academy of Dermatology.

[40]  B. Lang,et al.  Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. , 1994, The Journal of pediatrics.

[41]  S. Halevy,et al.  Lichenoid drug eruptions. , 1993, Journal of the American Academy of Dermatology.

[42]  M. Rieder,et al.  Drug‐induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides , 1992, Clinical pharmacology and therapeutics.

[43]  V. Ruocco,et al.  Pemphigus and Bullous Pemphigoid due to Drugs , 1991, International journal of dermatology.

[44]  S. Spielberg,et al.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. , 1988, The Journal of clinical investigation.

[45]  C. Dollery,et al.  HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS: INFLUENCE OF HLA-DR AND SEX ON SUSCEPTIBILITY , 1980, The Lancet.

[46]  V. Tozzi Pharmacogenetics of antiretrovirals. , 2010, Antiviral research.

[47]  E. Ozkaya Fixed drug eruption: state of the art. , 2008, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[48]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[49]  J. Roujeau,et al.  Drug-Induced Skin, Nail and Hair Disorders , 2007, Drug safety.

[50]  T. F. Downham,et al.  Furosemide-induced bullous pemphigoid: case report and review of literature. , 2006, Journal of drugs in dermatology : JDD.

[51]  L. Maas,et al.  Serum sickness-like reactions in patients receiving intravenous infliximab. , 2006, The Journal of emergency medicine.

[52]  S. Knowles,et al.  Should Celecoxib Be Contraindicated in Patients Who Are Allergic to Sulfonamides? , 2001, Drug safety.

[53]  B. Pomeranz,et al.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. , 1998, JAMA.

[54]  F. Klopp Guidelines of care for cutaneous adverse drug reactions , 1996 .

[55]  F. Dove Drug-induced lupus , 1982 .

[56]  M. Blaiss,et al.  Drug allergy. , 1988, Pediatric clinics of North America.

[57]  W. Falk,et al.  Successful treatment of lithium-induced acne. , 1986, Journal of Clinical Psychiatry.

[58]  J. Gõmez Orbaneja,et al.  [Toxic epidermal necrolysis]. , 1967, Revista clinica espanola.